Tech Company Financing Transactions
Septerna Funding Round
Septerna, based in San Francisco, secured $100 million from Third Rock Ventures, BVF Partners and Casdin Capital.
Transaction Overview
Company Name
Announced On
2/3/2022
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
Third Rock Ventures (Lead Investor) (Jeffrey Finer)
Proceeds Purpose
The Series A financing will enable Septerna to advance its emerging pipeline of novel GPCR-targeted drug programs, enabled by the Native Complex Platform and spanning multiple therapeutic areas.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
250 East Grand Ave. 65
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Our mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining the potential of high-value GPCR drug targets with the power of state-of-the-art small molecule drug discovery technologies. Septerna's Native Complex Platform is the engine that will make this happen, moving ideas for disease-modifying therapies from possibility to reality.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 2/3/2022: Onramper venture capital transaction
Next: 2/3/2022: CoinTracker venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs